ChondroGene Collects Milestone Payment from Pfizer
Toronto-based ChondroGene last week reported a $1.58 million milestone payment from Pfizer in research on osteoarthritis markers. The payment is part of a two-year agreement begun in 2002 that includes an equity investment and regular quarterly payments that will total $7.5 million, exclusive of milestones and royalties. The company has created a human-cartilage-specific microarray, the ChondroChip.
PamGene Spins Off Check-Points